Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Equity Ratio (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Equity Ratio for 13 consecutive years, with 0.24 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 180.26% to 0.24 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.24 through Dec 2025, up 180.26% year-over-year, with the annual reading at 0.24 for FY2025, 180.26% up from the prior year.
  • Equity Ratio hit 0.24 in Q4 2025 for Coherus Oncology, up from 0.17 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.27 in Q2 2025 to a low of 0.49 in Q1 2025.
  • Historically, Equity Ratio has averaged 0.08 across 5 years, with a median of 0.12 in 2024.
  • Biggest five-year swings in Equity Ratio: crashed 2406.41% in 2023 and later soared 318.78% in 2025.
  • Year by year, Equity Ratio stood at 0.14 in 2021, then tumbled by 298.66% to 0.29 in 2022, then fell by 7.5% to 0.31 in 2023, then increased by 4.21% to 0.29 in 2024, then surged by 180.26% to 0.24 in 2025.
  • Business Quant data shows Equity Ratio for CHRS at 0.24 in Q4 2025, 0.17 in Q3 2025, and 0.27 in Q2 2025.